Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease

Although guidelines recommend amikacin (AMK) inhalation therapy for difficult-to-treat nontuberculous mycobacterial lung disease (NTM-LD), data are limited regarding the safety and clinical efficacy of this salvage therapy. We retrospectively evaluated the treatment outcomes of 77 patients with refr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Jhun, Byung Woo, Yang, Bumhee, Moon, Seong Mi, Lee, Hyun, Park, Hye Yun, Jeon, Kyeongman, Kwon, O Jung, Ahn, Jungmin, Moon, Il Joon, Shin, Sung Jae, Daley, Charles L., Koh, Won-Jung
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2018
Matèries:
Clinical Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6021683/
https://ncbi.nlm.nih.gov/pubmed/29661870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00011-18
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars